Mesa Laboratories (NASDAQ:MLAB) was downgraded by research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Thursday.

Other research analysts have also recently issued research reports about the company. TheStreet cut Mesa Laboratories from a “b-” rating to a “c” rating in a research report on Tuesday, August 21st. Zacks Investment Research upgraded Mesa Laboratories from a “hold” rating to a “buy” rating and set a $248.00 target price on the stock in a research report on Wednesday, July 11th. Finally, ValuEngine cut Mesa Laboratories from a “buy” rating to a “hold” rating in a report on Thursday, October 4th.

Mesa Laboratories stock opened at $172.40 on Thursday. Mesa Laboratories has a 12-month low of $122.35 and a 12-month high of $224.95. The company has a current ratio of 2.10, a quick ratio of 1.55 and a debt-to-equity ratio of 0.36. The stock has a market capitalization of $714.78 million, a price-to-earnings ratio of 27.90 and a beta of 0.24.

Mesa Laboratories (NASDAQ:MLAB) last released its earnings results on Tuesday, July 31st. The medical instruments supplier reported $1.06 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.79 by $0.27. Mesa Laboratories had a positive return on equity of 15.92% and a negative net margin of 0.25%. The firm had revenue of $25.14 million for the quarter. As a group, equities analysts anticipate that Mesa Laboratories will post 7.09 earnings per share for the current fiscal year.

In other news, Director Michael T. Brooks sold 2,700 shares of the business’s stock in a transaction dated Monday, September 10th. The stock was sold at an average price of $195.39, for a total transaction of $527,553.00. Following the sale, the director now directly owns 27,750 shares in the company, valued at $5,422,072.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director David M. Kelly sold 700 shares of the business’s stock in a transaction dated Thursday, September 13th. The stock was sold at an average price of $190.01, for a total value of $133,007.00. Following the sale, the director now owns 3,600 shares in the company, valued at $684,036. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 4,400 shares of company stock worth $864,060. Company insiders own 15.00% of the company’s stock.

Several large investors have recently added to or reduced their stakes in the company. Wells Fargo & Company MN lifted its stake in shares of Mesa Laboratories by 12.4% in the first quarter. Wells Fargo & Company MN now owns 6,631 shares of the medical instruments supplier’s stock worth $985,000 after acquiring an additional 729 shares during the period. Schwab Charles Investment Management Inc. lifted its stake in shares of Mesa Laboratories by 8.9% in the first quarter. Schwab Charles Investment Management Inc. now owns 15,491 shares of the medical instruments supplier’s stock worth $2,300,000 after acquiring an additional 1,268 shares during the period. BlackRock Inc. lifted its stake in shares of Mesa Laboratories by 7.7% in the first quarter. BlackRock Inc. now owns 189,286 shares of the medical instruments supplier’s stock worth $28,098,000 after acquiring an additional 13,568 shares during the period. Stifel Financial Corp acquired a new position in shares of Mesa Laboratories in the first quarter worth approximately $1,011,000. Finally, UBS Group AG lifted its stake in shares of Mesa Laboratories by 81.1% in the first quarter. UBS Group AG now owns 5,593 shares of the medical instruments supplier’s stock worth $830,000 after acquiring an additional 2,505 shares during the period. Institutional investors own 71.91% of the company’s stock.

Mesa Laboratories Company Profile

Mesa Laboratories, Inc designs, manufactures, and markets quality control instruments and disposable products. The company's Instruments segment offers data loggers, which are precision instruments used in critical manufacturing, quality control, and validation applications; medical meters and calibration solutions used to test various parameters of the dialysis fluid, and the calibration and operation of the dialysis machine; gas flow calibration and air sampling equipment that are used for industrial hygiene assessments, calibration of gas metering equipment, and environmental air monitoring; and torque testing systems used for measure bottle cap tightness.

Featured Article: Trading Penny Stocks

Receive News & Ratings for Mesa Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesa Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.